Cardioprotection for radiation-induced heart disease in breast cancer patients

Radiotherapy is an integral part of early breast cancer treatment, when breast-conserving surgery is performed. Heart disease caused by radiotherapy can include pericardial lesions, cardiac dysfunction, valvular defects, coronary artery damage, and cardiac arrhythmias. Risk factors primarily include those related to the mean heart dose of radiation, but with the development of modern radiotherapy techniques, this problem is optimistically decreasing. However, concurrent pharmacological anticancer therapies still significantly impact the vessels and heart. The key problem, however, is pre-existing heart disease, often based on atherosclerosis or arterial hypertension. Efforts should be made to ensure that radiotherapy produces at most permissive cardiotoxicity, which will not affect the quality of life or survival. Hence, effective pharmacotherapy for primary and secondary cardioprotection is searching.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-01-06
DOI
https://doi.org/10.3389/fphar.2025.1742769
Primary Topic
Chemotherapy-induced cardiotoxicity and mitigation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cardioprotection for radiation-induced heart disease in breast cancer patients

Sabina Mędrek, Sebastian Szmit, Kasper Rolek, Jakub Homotnik
Frontiers in Pharmacology
Chemotherapy-induced cardiotoxicity and mitigation
article

Cardioprotection for radiation-induced heart disease in breast cancer patients

Sabina Mędrek, Sebastian Szmit, Kasper Rolek, Jakub Homotnik
article en

Abstract

Radiotherapy is an integral part of early breast cancer treatment, when breast-conserving surgery is performed. Heart disease caused by radiotherapy can include pericardial lesions, cardiac dysfunction, valvular defects, coronary artery damage, and cardiac arrhythmias. Risk factors primarily include those related to the mean heart dose of radiation, but with the development of modern radiotherapy techniques, this problem is optimistically decreasing. However, concurrent pharmacological anticancer therapies still significantly impact the vessels and heart. The key problem, however, is pre-existing heart disease, often based on atherosclerosis or arterial hypertension. Efforts should be made to ensure that radiotherapy produces at most permissive cardiotoxicity, which will not affect the quality of life or survival. Hence, effective pharmacotherapy for primary and secondary cardioprotection is searching.

Frontiers in PharmacologyVol. 16
National Institute of Oncology (HU), Lublin Oncology Center (PL), Postgraduate School of Molecular Medicine (PL)
Good health and well-being
Openalex Percentile: Top 96%
Chemotherapy-induced cardiotoxicity and mitigation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.